Central Nervous System Stimulants and Related Drugs
Objectives
When you reach the end of this chapter, you will be able to do the following:
2 Review the key terms as they relate to the central nervous system and stimulant drugs.
3 Identify the various central nervous system stimulant drugs.
Drug Profiles
Key Terms
Amphetamines A class of stimulant drugs that includes amphetamine sulfate and all of its drug derivatives. (p. 206)
Analeptics Central nervous system (CNS) stimulants that have generalized effects on the brainstem and spinal cord, which produce an increase in responsiveness to external stimuli and stimulate respiration. (p. 212)
Anorexiants Drugs used to control or suppress appetite. (p. 208)
Attention deficit hyperactivity disorder (ADHD) A syndrome characterized by difficulty in maintaining concentration on a given task and/or hyperactive behavior; may affect children, adolescents, and adults. The term attention deficit disorder (ADD) has been absorbed under this broader term. (p. 205)
Cataplexy A condition characterized by abrupt attacks of muscular weakness and hypotonia triggered by an emotional stimulus such as joy, laughter, anger, fear, or surprise. It is often associated with narcolepsy. (p. 206)
Central nervous system (CNS) stimulants Drugs that stimulate specific areas of the brain or spinal cord. (p. 204)
Ergot alkaloids Drugs that narrow or constrict blood vessels in the brain and provide relief of pain for certain migraine headaches. (p. 209)
Migraine A common type of recurring painful headache characterized by a pulsatile or throbbing quality, incapacitating pain, and photophobia. (p. 205)
Narcolepsy A syndrome characterized by sudden sleep attacks, cataplexy, sleep paralysis, and visual or auditory hallucinations at the onset of sleep. (p. 205)
Serotonin receptor agonists A class of CNS stimulants used to treat migraine headaches; they work by stimulating 5-hydroxytryptamine 1 receptors in the brain and are sometimes referred to as selective serotonin receptor agonists or triptans. (p. 209)
Sympathomimetic drugs CNS stimulants such as noradrenergic drugs (and, to a lesser degree, dopaminergic drugs) whose actions resemble or mimic those of the sympathetic nervous system. (p. 204)
http://evolve.elsevier.com/Lilley
• Answer Key—Textbook Case Studies
• Critical Thinking and Prioritization Questions
• Review Questions for the NCLEX® Examination
Anatomy, Physiology, and Pathophysiology Overview
The central nervous system (CNS) is a very complex system in the human body. Many therapeutic drugs either work in the CNS or cause adverse effects in the CNS. Activity of the CNS is regulated by a checks-and-balances system that consists of excitatory and inhibitory neurotransmitters and their corresponding receptors in the brain and spinal cord tissues. CNS stimulation results from either excessive stimulation of excitatory neurons or blockade of inhibitory neurons. Central nervous system (CNS) stimulants are a broad class of drugs that stimulate specific areas of the brain or spinal cord. Most CNS stimulant drugs act by stimulating the excitatory neurons in the brain. These neurons contain receptors for excitatory neurotransmitters, including dopamine (dopaminergic drugs), norepinephrine (adrenergic drugs), and serotonin (serotonergic drugs). Dopamine is a metabolic precursor of norepinephrine, which is also a neurotransmitter in the sympathetic nervous system. Actions of adrenergic drugs often resemble or mimic the actions of the sympathetic nervous system. For this reason, adrenergic drugs (and, to a lesser degree, dopaminergic drugs as well) are also called sympathomimetic drugs. Other sympathomimetic drugs are discussed further in Chapter 18.
CNS stimulant drugs are classified in three ways. The first is on the basis of chemical structural similarities. Major chemical classes of CNS stimulants include amphetamines, serotonin agonists, sympathomimetics, and xanthines (Table 13-1). Second, these drugs can be classified according to their site of therapeutic action in the CNS (Table 13-2). Finally, they can be categorized according to five major therapeutic usage categories for CNS stimulant drugs (Table 13-3). These include anti–attention deficit, antinarcoleptic, anorexiant, antimigraine, and analeptic drugs. Anorexiants are drugs used to control obesity by suppression of appetite. Analeptics are drugs used for specific CNS stimulation in certain clinical situations. Some therapeutic overlap exists among these drug categories.
TABLE 13-1
STRUCTURALLY RELATED CNS STIMULANTS
CHEMICAL CATEGORY | CNS STIMULANTS AND RELATED DRUGS |
Amphetamines and related stimulants | dextroamphetamine, methamphetamine, benzphetamine, methylphenidate, dexmethylphenidate, |
Serotonin agonists | almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan |
Sympathomimetics | phentermine, phendimetrazine |
Xanthines | caffeine, theophylline, aminophylline |
Miscellaneous | modafinil, armodafinil, orlistat (lipase inhibitor), doxapram (analeptic) |
TABLE 13-2
CNS STIMULANTS: SITE OF ACTION
PRIMARY SITE OF ACTION | CNS STIMULANTS |
Cerebrovascular system, 5-HT1D/1B receptors | Serotonin agonists |
Cerebral cortex | Amphetamines, phenidates, modafinil, armodafinil |
Hypothalamic and limbic regions | Anorexiants |
Medulla and brainstem | Analeptics |
TABLE 13-3
CNS STIMULANTS AND RELATED DRUGS: THERAPEUTIC CATEGORIES
CATEGORY | DRUGS |
Anti-ADHD | dextroamphetamine, lisdexamfetamine, methamphetamine, methylphenidate, atomoxetine (norepinephrine reuptake inhibitor) |
Antinarcoleptic | dextroamphetamine, methamphetamine, methylphenidate, modafinil, armodafinil |
Anorexiant | methamphetamine, phentermine, phendimetrazine, diethylpropion, benzphetamine, orlistat (lipase inhibitor) |
Antimigraine | almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan (serotonin agonists); dihydroergotamine mesylate, ergot-amine tartrate with caffeine (ergot alkaloids) |
Analeptic | caffeine, doxapram, aminophylline, theophylline, modafinil, armodanafil (antinarcoleptic) |
ADHD, Attention deficit hyperactivity disorder; CNS, central nervous system.
Attention Deficit Hyperactivity Disorder
Attention deficit hyperactivity disorder (ADHD), formerly known as attention deficit disorder (ADD), is the most common psychiatric disorder in children, affecting 3% to 10% of school-age children. Boys are affected from two to nine times more often than girls, although the disorder may be underdiagnosed in girls. Primary symptoms of ADHD are a developmentally inappropriate ability to maintain attention span and/or the presence of hyperactivity and impulsivity. The disorder may involve predominantly attention deficit, predominantly hyperactivity or impulsivity, or a combination of both. It usually begins before 7 years of age, sometimes earlier than 4 years of age. It can officially be diagnosed when symptoms last at least 6 months and occur in at least two different settings (e.g., home and school), according to the Diagnostic and Statistical Manual of Mental Disorders. Many children outgrow ADHD, but adult ADHD is also common. Drug therapy for both childhood and adult ADHD is essentially the same. There is some social controversy regarding possible overdiagnosis of, and overmedication for this disorder. Studies in twins indicate a degree of genetic predisposition and familial heritability. The disorder is commonly associated with other forms of mental illness, including depression, bipolar disorder, anxiety, and learning difficulties.
Narcolepsy
Narcolepsy is an incurable neurologic condition in which patients unexpectedly fall asleep in the middle of normal daily activities. These “sleep attacks” are reported to cause car accidents or near-misses in 70% or more of patients. Another major symptom of the disease is dysfunctional rapid eye movement sleep (see Chapter 12). Cataplexy is an associated symptom in at least 70% of narcolepsy cases. It involves sudden acute skeletal muscle weakness. The condition is often associated with strong emotions (e.g., joy, anger), and commonly the knees buckle and the individual falls to the floor while still awake. Men and women are equally affected, with approximately 100,000 cases in the United States. Some genetic markers have been identified. Roughly half of patients with narcolepsy experience migraine headaches as well.
Obesity
According to the National Institutes of Health and the Centers for Disease Control and Prevention, approximately 30% of Americans are obese and nearly two thirds (64.5%) are overweight. This translates into more than 72 million obese adults, with a higher incidence of obesity among women and minorities. Obesity was formerly defined as being 20% or more above one’s ideal body weight based on population statistics for height, body frame, and gender. More recent data are based on a measurement known as the body mass index (BMI), defined as weight in kilograms divided by height in meters squared (i.e., BMI = weight [kg] ÷ [height (m)]2). Overweight is now defined as a BMI of 25 to 29.9, whereas obesity is now defined as a BMI of 30 or higher. At any given time, one third of women and one quarter of men are trying to lose weight. Moreover, the incidence of obesity in young people 6 to 19 years of age has more than tripled since 1980. The pathophysiology of obesity is not fully understood, but calorie excess, disordered metabolism, and other factors are hypothesized. Obesity increases the risk for hypertension, dyslipidemia, coronary artery disease, stroke, type 2 diabetes mellitus, gallbladder disease, gout, osteoarthritis, sleep apnea, and certain types of cancer, including breast and colon cancer. An estimated 80% of diabetes risk in the United States can be attributed to excess weight. Some 112,000 deaths each year are linked to obesity. The related health care costs alone are currently estimated at more than $140 billion. Yet many people who attempt weight loss do so for cosmetic reasons rather than health reasons. Obese people are often stigmatized, at times even by the health care professionals treating them.
Migraine
A migraine is a common type of recurring headache, usually lasting from 4 to 72 hours. Typical features include a pulsatile quality with pain that worsens with each pulse. The pain is most commonly unilateral but may occur on both sides of the head. Associated symptoms include nausea, vomiting, photophobia (avoidance of light), and phonophobia (avoidance of sounds). In addition, some migraines are accompanied by an aura, which is a predictive set of altered visual or other senses (formerly termed classic migraine). However, the majority of migraines are without an aura (formerly termed common migraine). Migraines affect about 30 million people in the United States, with a reported incidence in females roughly three times that in males. Migraine headaches have been classified by the World Health Organization as one of the 19 most disabling diseases worldwide, with approximately 64 to 150 million workdays lost annually. Migraines commonly begin after 10 years of age and peak between the mid-twenties and early forties. They often fade after 50 years of age. Familial inheritance of migraine is well recognized. Precipitating factors include stress, hypoglycemia, menses, endogenous estrogen (including oral contraceptives), exercise, and intake of alcohol, caffeine, cocaine, nitroglycerin, aspartame, and the food additive monosodium glutamate (MSG). Over 50% of patients with narcolepsy report nocturnal migraines. Historically, there have been several theories regarding the cause of migraines, including the “vascular hypothesis” and the “neurovascular hypothesis.” Most recent evidence points to decreased serotonin levels. Thus, the majority of current investigations involve drugs that can increase the serotonin levels.
Analeptic-Responsive Respiratory Depression Syndromes
Neonatal apnea, or periodic cessation of breathing in newborn babies, is a common condition seen in neonatal intensive care units. It occurs in about 25% of premature infants whose pulmonary and CNS structures, including the medullary centers that control breathing, have not completed their gestational development because of preterm birth. Infants undergoing prolonged mechanical ventilation, especially at high pressures, often develop a chronic lung disease known as bronchopulmonary dysplasia, for which caffeine can be helpful. Postanesthetic respiratory depression occurs when a patient’s spontaneous respiratory drive does not resume adequately and in a timely manner after general anesthesia. Respiratory depression may also be secondary to abuse of some drugs. Hypercapnia, or elevated blood levels of carbon dioxide, is often associated with later stages of chronic obstructive pulmonary disease (COPD). Analeptic drugs such as theophylline, aminophylline, caffeine, and doxapram may be used to treat one or more of these conditions. Analeptic drugs are now used much less frequently than they were in the earlier days of general anesthesia. This is because of advances in intensive respiratory care, including mechanical ventilation and improved anesthetic techniques, as well as the availability of newer medications with less toxicity.
Pharmacology Overview
Drugs for Attention Deficit Hyperactivity Disorder and Narcolepsy
CNS stimulants are the first-line drugs of choice for both ADHD and narcolepsy. They are potent drugs with a strong potential for tolerance and psychological dependence (addiction; see Chapter 17). They are classified as Schedule II drugs under the Controlled Substance Act. Although there has been some public controversy regarding their use in ADHD, these drugs have led to a 65% to 75% improvement in symptoms in treated patients compared with a placebo. In general, CNS stimulants elevate mood, produce a sense of increased energy and alertness, decrease appetite, and enhance task performance impaired by fatigue or boredom. Two of the oldest known stimulants are cocaine and amphetamine, which are prototypical drugs for this class. Caffeine, contained in coffee and tea, is another plant-derived CNS stimulant.
Amphetamine sulfate was first synthesized in the late 1800s. It was subsequently used to treat narcolepsy and then to prolong the alertness of soldiers during World War II. Later derivatives of this drug, which are still used clinically, include its d-isomer dextroamphetamine sulfate, methamphetamine hydrochloride, benzphetamine, and mixed amphetamine salts—salts of both amphetamine and dextroamphetamine. They are often collectively referred to simply as amphetamines. Methylphenidate, a synthetic amphetamine derivative, was first introduced for the treatment of hyperactivity in children in 1958. Its d-isomer is the drug dexmethylphenidate. The phenidates are also Schedule II drugs. All of these amphetamine-related drugs are used to treat ADHD and/or narcolepsy. Nonamphetamine stimulants include pemoline and modafinil. In 2005, pemoline was taken off the market because of reports of liver failure associated with its use.
Atomoxetine is a nonstimulant drug that is also used to treat ADHD. Atomoxetine is a norepinephrine reuptake inhibitor. Because it is not an amphetamine, it is associated with a low incidence of insomnia and has low abuse potential. Another advantage is that phone-in refills are allowed for this drug (as opposed to Schedule CII drugs, which require a written prescription). One of the newest drugs in the ADHD arsenal is lisdexamfetamine (Vyvanse). It is a prodrug for dextroamphetamine, meaning it is converted in the body to dextroamphetamine.
Mechanism of Action and Drug Effects
Amphetamines stimulate areas of the brain associated with mental alertness, such as the cerebral cortex and the thalamus. Pharmacologic actions of CNS stimulants are similar to the actions of the sympathetic nervous system in that the CNS and respiratory systems are the primary systems affected. CNS effects include mood elevation or euphoria, increased mental alertness and capacity for work, decreased fatigue and drowsiness, and prolonged wakefulness. The respiratory effects most commonly seen are relaxation of bronchial smooth muscle, increased respiration, and dilation of pulmonary arteries.
The amphetamines and phenidates increase the effects of norepinephrine and dopamine in CNS synapses by increasing their release and blocking their reuptake. As a result, both neurotransmitters are in contact with their receptors longer, which lengthens their duration of action. Modafinil is also classified as an analeptic. It promotes wakefulness like the amphetamines and phenidates. It lacks sympathomimetic properties, however, and appears to work primarily by reducing gamma-aminobutyric acid (GABA)–mediated neurotransmission in the brain. GABA is the principal inhibitory neurotransmitter in the brain. The nonstimulant drug atomoxetine is also being used to treat ADHD. It works in the CNS by selective inhibition of norepinephrine reuptake.
Indications
Various amphetamine derivatives, including methylphenidate, are currently used to treat both ADHD and narcolepsy. Dexmethylphenidate is currently indicated for ADHD alone. Amphetamine sulfate was also used to treat obesity in the early to mid twentieth century. However, the only amphetamines currently approved for this indication are benzphetamine and methamphetamine (see Anorexiants). The nonamphetamine stimulant modafinil is indicated for narcolepsy.
Specialists sometimes recommend periodic “drug holidays” (e.g., 1 day per week) without medication to diminish the addictive tendencies of the stimulant drugs. School-age children often do not take these drugs on weekends and school vacations.
Contraindications
Contraindications to the use of amphetamine and nonamphetamine stimulants include known drug allergy or cardiac structural abnormalities. These drugs can also exacerbate the following conditions: marked anxiety or agitation, Tourette’s syndrome and other tic disorders (hyperstimulation), hypertension, and glaucoma (can increase intraocular pressure; see Chapter 57). The drugs must not be used in patients who have received therapy with any monoamine oxidase inhibitor (MAOI) in the preceding 14 days (see Chapter 16). Contraindications specific to atomoxetine include drug allergy, glaucoma, and recent MAOI use.
Adverse Effects
Both amphetamine and nonamphetamine stimulants have a wide range of adverse effects that most often arise when these drugs are administered at high doses. These drugs tend to “speed up” body systems. For example, effects on the cardiovascular system include increased heart rate and blood pressure. Other adverse effects include angina, anxiety, insomnia, headache, tremor, blurred vision, increased metabolic rate (beneficial in treatment of obesity), gastrointestinal (GI) distress, dry mouth, and worsening of or new onset of psychiatric disorders, including mania, psychoses, or aggression. Common adverse effects associated with atomoxetine include headache, abdominal pain, vomiting, anorexia, and cough.
Interactions
Drug interactions associated with these drugs vary greatly from class to class. Table 13-4 summarizes some of the more common interactions for all drug classes in this chapter.
TABLE 13-4
CNS STIMULANTS: COMMON DRUG INTERACTIONS
DRUG | INTERACTING DRUGS | MECHANISM | RESULT |
Amphetamine and Nonamphetamine Stimulants | |||
Amphetamines (various salts) methylphenidate | CNS stimulants | Additive toxicities | Cardiovascular adverse effects, nervousness, insomnia |
MAOIs | Increased release of catecholamines | Headaches, dysrhythmias, severe hypertension | |
Atomoxetine | Sympathomimetic drugs | Enhanced SNS effects | Cardiovascular adverse effects (dysrhythmias, tachycardia, hypertension) |
CYP2D6 inhibitors (MAOIs, paroxetine) | Reduced metabolism of atomoxetine | Enhanced atomoxetine toxicity | |
Anorexiants and Analeptics | |||
phentermine | CNS stimulants | Additive toxicities | Nervousness, insomnia, dysrhythmias, seizures |
MAOIs | Increased release of catecholamines | Headaches, dysrhythmias, severe hypertension | |
Serotonergic drugs | Additive toxicity | Cardiovascular adverse effects, nervousness, insomnia, convulsions | |
Serotonin Agonists | |||
sumatriptan and others | Ergot alkaloids, SSRIs, MAOIs | Additive toxicity | Cardiovascular adverse effects, nervousness, insomnia, convulsions |
Ergot Alkaloids | |||
D.H.E.45, Caffergot | Protease inhibitors, azole antifungals, macrolide antibiotics | Increased ergot levels | Acute ergot toxicity; nausea, vomiting, hypotension or hypertension, seizures, coma, death; use with ergot alkaloids is contraindicated |
Dosages
For dosage information, see the table on p. 211.
Drug Profiles
Amphetamines and Related Stimulants
The principal drugs used to treat ADHD and narcolepsy are amphetamines and nonamphetamine stimulants. Atomoxetine, a nonstimulant drug, is also used for ADHD.
♦ amphetamines
The various amphetamine salts are the prototypical CNS stimulants used to treat ADHD and narcolepsy. Amphetamine is available in prescription form only for oral use, both as single-component dextroamphetamine sulfate (Dexedrine) and as a mixture of dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine sulfate, and amphetamine aspartate (Adderall).
Pharmacokinetics (dextroamphetamine)
Route | Onset of Action | Peak Plasma Concentration | Elimination Half-life | Duration of Action |
PO | 30-60 min | 90-120 min | 7-14 hr | 10 hr |
♦ methylphenidate
Methylphenidate (Ritalin) was the first prescription drug indicated for ADHD and continues to be the most widely prescribed drug for the treatment of ADHD and is also used for narcolepsy. Extended-release dosage forms include Ritalin SR, Concerta, and Metadate CD. There is some controversy regarding drug therapy for ADHD. Some parents may be understandably apprehensive regarding this type of drug therapy. However, with proper diagnosis of the disorder, proper dosing of the drug, and regular medical monitoring, many children can achieve significant improvement in school performance and social skills. Psychosocial problems within a child’s family need to be ruled out or addressed if they are contributing to the child’s problems, regardless of whether the medication is prescribed.
Pharmacokinetics (immediate release)
Route | Onset of Action | Peak Plasma Concentration | Elimination Half-life | Duration of Action |
PO | 30-60 min | 6-8 hr | 1-3 hr | 4-6 hr |
atomoxetine
Atomoxetine (Strattera) is approved for treating ADHD in children older than 6 years of age and in adults. This medication is not a controlled substance because it lacks addictive properties, unlike amphetamines and phenidates. For this reason, it has rapidly gained popularity as a therapeutic option for treating ADHD. In September 2005, however, the FDA issued a warning describing cases of suicidal thinking and behavior in small numbers of adolescent patients receiving this medication, similar to its previous warnings regarding adolescent use of antidepressant medications (see Chapter 16). Prescribers are advised to work with parents in providing prudent monitoring of any young patients taking this medication and to promptly reevaluate patients showing any behavioral symptoms of concern.
Route | Onset of Action | Peak Plasma Concentration | Elimination Half-life | Duration of Action |
PO | 60 min | 1-2 hr | 5-24 hr | 24-120 hr |
modafinil
Modafinil (Provigil) is indicated for improvement of wakefulness in patients with excessive daytime sleepiness associated with narcolepsy and also with shift work sleep disorder. It has less abuse potential than amphetamines and methylphenidate and is a Schedule IV drug. A related drug is armodafinil (Nuvigil), which is similar to modafinil.
Route | Onset of Action | Peak Plasma Concentration | Elimination Half-life | Duration of Action |
PO | 1-2 months∗ | 2-4 hr | 8-15 hr | Unknown |